W

hen it comes to weight loss, Arena Pharmaceuticals is throwing in the towel.

The small San Diego biotech company had once expected its anti-obesity drug, Belviq, to be a blockbuster — after all, more than one-third of Americans are obese. But the market wasn’t interested, and sales never lived up to expectations — leading the company to slash its employee count by 120, nearly three-quarters of its workforce.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X